With FDA spanking, Biocon and Mylan face new hurdle for Lantus challenger

A two-week FDA inspection has turned up more issues at the Malaysian manufacturing facilities where Biocon will manufacture its rival to Sanofi's Lantus long-acting insulin. Biocon says the new Form 483 won't affect its plans to get to market with the candidate that it is sharing with Mylan.